Gilead (GILD) Begins Phase 3 Trial Evaluating GS-1101 for Lymphocytic Leukemia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/25/2026

1. NVDA
2. SPY
3. AAPL
4. XPEV
5. DKS
6. USO
7. BMO
8. VEEV
9. GRML
10. AMD

Go back to Gilead (GILD) Begins Phase 3 Trial Evaluating GS-1101 for Lymphocytic Leukemia
Gilead Sciences (NASDAQ: GILD) Delayed: 148.77 +2.03 (1.38%)
Previous Close $146.74    52 Week High $108.63 
Open $146.60    52 Week Low $71.39 
Day High $148.94    P/E 82.19 
Day Low $145.58    EPS $1.81 
Volume 4,630,492